Introduction
Hematopoietic stem-cell transplantation often offers patients with progressive malignant hematological diseases the only chance for cure. However, immune competent T cells in the graft can initiate immune reactions that cause severe graft-versus-host disease (GVHD) with potentially fatal outcome. The risk of GVHD is influenced by the constellation of major and minor histocompatibility antigens (HLA) between donor and recipient. Matching donor and recipient for HLA improves the outcome of transplantation. Certain genes may also affect the outcome by modulating the immune response to infections and inflammation reactions. Among these genes, cytokines play an important role by regulating the growth, differentiation and function of cells in the immune system and thereby influencing also the occurrence and severity of GVHD reactions after transplant. 1 Genetic polymorphisms of cytokines may affect their transcription or translation and may result in different expression or function of the corresponding proteins with different effects. 2 Autoimmune diseases like Crohn's disease and the GVHD immune reaction post transplant share some pathways in part. Thus, it was shown that gene polymorphisms of NOD2 and TLR-4 genes have an influence on the clinical outcome of Crohn's disease as well on the occurrence and severity of GVHD. [3] [4] [5] [6] [7] [8] [9] Recently, a gene variant of the interleukin-23 receptor (IL-23R-1142G4A) was found to be strongly associated with Crohn's disease. 10, 11 IL-23 is a new member of the IL-12 family that plays a critical role in promoting inflammatory responses mediated by type 1 helper T cells. IL-23 and IL-12 share same molecule structure. The IL-12 cytokine consists of covalently linked p40 and p35 subunits, and IL-23 is composed of the IL-12 p40 chain which is associated with a p19 subunit. The heterodimerized IL-23 receptor is composed of a shared IL-12 receptor b1 (IL-12Rb1) and an IL-12Rb2-related molecule called IL-23R in which the coding variant 1142G4A is located (Figure 1 ). Both cytokines induce proliferation and interferon (IFN)-g production by T cells, which are also mediators of acute GVHD reactions. 12, 13 We analyzed a single-nucleotide polymorphism (SNP) in the gene for IL-23R in a cohort of 221 transplant recipients and their HLA-identical sibling donors designated cohort 1. The SNP correlate with gene function and protection of disease. A statistically significant finding in this cohort led to independent testing in a second cohort of 186 recipients and their HLA-identical unrelated donors. Results of a combined analysis demonstrated a significant association between polymorphisms in the exon 9 gene region of the donor's IL-23 gene and the risk of acute GVHD.
Patients and methods

Patients
The entire study population consisted of 407 transplant recipients and their HLA-identical donors who were transplanted at the University Hospital of Essen between October 1995 and March 2007. All patients received unmanipulated grafts containing T cells. The molecular analyses were performed without prior knowledge of the GVHD status of the patients analyzed. Pretransplant histocompatibility testing of donors and patients generally consisted of low-resolution HLA-A, -B, -C and highresolution HLA-DRB1, -DQB1 DNA-based typing according to standard methods. 14 Inclusion criteria were the availability of pretransplantation blood samples, the use of methotrexate and cyclosporine for prophylaxis against GVHD. The conditioning regimens have been previously published. 15 The study was divided into two phases and included two separate cohorts. The initial cohort consisted of 221 recipients with sibling donors previously assembled for a different study. We used this cohort to screen for an association between GVHD and polymorphism in the IL-23R gene. The second cohort included 186 recipients with their HLA-identical unrelated donors. There were significant differences between these groups in donor age, sex constellation between recipient and donor, disease stage and conditioning with total body irradiation ( Table 1) . A final analysis of clinical end points included both cohorts. All patients and donors gave their written informed consent according to protocols approved by Institutional Review Board on Medical Ethics at the University Hospital of Essen.
Nomenclature of the single-nucleotide polymorphism
The IL-23R gene contains an extracellular domain, a single transmembrane domain and a 252 amino-acid cytoplasmic domain. The IL-23R (1142G4A, protein Arg381Gln) variant is located in the cytoplasmic domain at position 1142 of its nucleotide sequence. The polymorphism of that gene variant is the replacement of the nucleotide adenine (A) with guanine (G), which leads to the replacement of the commonly occurring amino-acid arginine with glutamine.
Isolation of genomic DNA DNA was prepared from peripheral blood mononuclear cells obtained from the donor and patient before the transplant using the phenol/chloroform method. 16 Genotyping of single-nucleotide polymorphism Genotyping for IL-23R Arg381Gln was analyzed by a Lightcycler protocol using the following hybridization probes: ACAgATCATTCCAAACTGggt-FL and gTTTTT gCAgAATTTCTgTTTTCTgATTT-p. The following primers were used: CTTTCCTTTCATTAgACAACAgAgg and AACTgAAATgACTAAATTTTggTgA. The primers for the PCR were synthesized by MWG Biotech (Ebersberg, Germany). The fluorescence-labeled sensor and anchor hybridization probes for the Lightcycler protocol were purchased from TIB MOLBIOL (Berlin, Germany). The sensor probes cover the SNP and exhibit a different melting temperature dependent on the binding to the wild type or variant allele. The anchor probes were designed to display a significantly higher melting temperature as compared to the corresponding sensor probes. PCR and subsequent melting curve analysis were performed using the Lightcycler device and software. Control samples confirmed by sequencing were included in each run.
Engraftment
Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count greater than 0.5 Â 10 9 /l. 
Statistical analysis
Acute GVHD and chronic GVHD were diagnosed and graded according to standard criteria. 17, 18 Death in remission was defined as any death occurring before the recurrence of the underlying disease. The cumulative rates of incidence of acute GVHD, chronic GVHD, and death in remission and overall survival were calculated with the use of the Kaplan-Meier method. 19 Differences between time-to-event distribution functions were compared by a log-rank test (Mantel-Haenszel). 20 A stepwise proportional hazards general linear model (PHGLM) analysis was used to evaluate interactions of different covariates on the analytical end point of TRM and severe acute GVHD. Covariates in PHGLM analyses were stratified according to severe acute GVHD (only for the end point TRM), age (p40 or 440 years), gender constellation (male patient with female donor or other), variations of IL-23R gene (variant on the donor side versus others and variant on the recipient side versus others). The most frequent (major) allele (M/M) was compared to the variant type (M/m or m/m): sibling donor versus unrelated donor, graft type (PBSC or bone marrow) and disease stage (advanced versus early disease stages) were analyzed. Conditional risk ratios (RR) and their 95% confidence intervals (CIs) were derived from PHGLM analyses after adjustment for significant covariates in the model. Any variable associated with a hazard ratio of 2.0 or greater or 0.5 or less or a P-value for trend of 0.05 or less in the first cohort was reevaluated in the second cohort.
The demographic characteristics of the groups were compared by means of descriptive methods, and significant differences were identified by means of the Fisher's exact test. Statistical analysis was performed using the SPSS software version 13.0. Only patients surviving more than 30 days were included in the analysis of acute GVHD. A minimum of 100 days of follow-up was the criterion for chronic GVHD.
Results
First cohort
In the first cohort of 221 recipients/donor pairs the IL-23R-1142G4A gene variant occurred with a frequency of 13.1% in recipients and 11.3% in donors. A homozygous gene variation was observed in only one recipient and in one donor, whereas all other recipients and donors with gene variants were heterozygous. Calculated allele frequencies were 6.8% for patients and 5.9% for donors for variant IL-23R gene. In 5.9% of all recipients and donor pairs, the IL-23R gene variant occurred at the recipient and donor side.
Recipients transplanted from donors with the IL-23R-1142G4A allele had a significantly lower incidence of severe (grades 3-4) acute GVHD (P ¼ 0.025). GVHD grades 3-4 occurred in 22% of recipients transplanted from donors with wild type of IL-23R gene as compared to only 4% of severe GVHD in recipients transplanted from donors with IL-23R-1142A/C gene variant. Also a significant trend was found when the patient showed up the genotype 1142A/C alone (P ¼ 0.021). A severe GVHD occurred in only 3.5% of patients as compared to 22% (Figure 1a) .
Second cohort
In the second cohort of 186 recipients transplanted from an unrelated donor, 13.9% of the donors and 12.2% of the recipients had the IL-23R gene variant-1142G4A. The calculated allele frequencies were 6.9% for donors and 6.1% for recipients. All recipients and donors were heterozygous for the IL-23R gene variant. In only 5% of donors and recipients did the gene variant occur in both. As shown in cohorts 1 and 2, recipients transplanted from donors with IL-23R variant had a significantly lower incidence of severe GVHD grades 3-4 of only 3.8% as compared to 25.2% in recipients transplanted from donors with the wild-type gene (P ¼ 0.02) (Figure 1b) . Also the incidence of acute GVHD grades 2-4 was lower (23.0 versus 48.0%, P ¼ 0.01) in the second cohort of 186 recipients transplanted from donors with the G/A genotype at the IL-23R 1142 locus. Surprisingly, no protective effect of the IL-23R gene variant on the occurrence of severe GVHD was seen when the gene variant was detected only on the recipient side in contrast to the results of the cohort 1 (GVHD grades 2-4, 56.4 versus 54.2%; GVHD grades 3-4, 22.3 versus 25.2%). The consistency of the effects between the two independent cohorts suggested that the IL-23R-1142G/A genotype in the donor was associated with a reduced risk for severe acute GVHD.
Incidence of GVHD and outcome of transplantation for IL-23R gene polymorphism located at position 1142 in the cytoplasmic domain Analysis of polymorphism in the IL-23R gene of the donor-recipient pairs and the risk of acute GVHD was performed next in the combined cohort of 407 recipients. A significant association with reduced incidence of severe acute GVHD was observed for IL-23R 1142A/G genotype on the donor side (3.9 versus 23.4%, P ¼ 0.003, Figure 2 ). The protective effect was also seen for acute GVHD grades 2-4 (31.6 versus 51%, P ¼ 0.043, Figure 3) . However, no significant trend was found when the IL-23R gene variant was detected on the recipient side (13.7 versus 23.4% for grades 3-4, P ¼ 0.20; and 42.6 versus 49.6% grades 2-4,
No significant association was found either between the incidence of chronic (extensive or limited) GHVD in patients transplanted from donors with the IL-23R gene variant or those transplanted from the wild type of IL-23R gene at 1142 loci at 3 years (79.1 versus 74.5%, not significant, P ¼ 0.77).
Estimates for death in remission at 5 years showed a clear advantage for patients transplanted from donors with IL-23R-gene variant (27.7±3.0% for wild type versus 11.7 ± 5.8% for gene variant on the donor side (P ¼ 0.028, Figure 4) , and for patients with IL-23R gene variant (27.3±3.0% for wild type versus 15.5±8% for gene variant at recipient side (P ¼ 0.043)). However, overall survival among the combined cohorts was not significantly associated with the genotype of IL-23R (60.6±3.3% for wild type versus 55.8 ± 8.2% for gene variant on the donor side at 5 years, and 59.9 ± 3.3% for wild type versus 56.5±8.3% for gene variant on the recipient side at 5 years). Although not significant, we observed a trend to a higher relapse rate for the gene variant of IL-23R (31.2 ± 3.2% for wild type versus 46.2 ± 9.2% for gene variant on the donor side at 5 years, and 29.4±3.2 for wild type versus 39.5 ± 8.2 for gene variant at recipient side at 5 years).
Engraftment
Median time to neutrophil engraftment after transplant was not different between the study groups (all median 16 days for recipients and donors).
Multivariate analysis for the occurrence of severe acute GVHD grades 3-4 and acute GVHD grades 2-4 For severe acute GVHD and acute GVHD grades 2-4, age (p40 or 440 years), gender constellation (male patient with female donor or other), variations of IL-23R gene (variant on the donor side versus others, and variant on the recipient side versus others), sibling donor versus unrelated donor, graft type (PBSC or bone marrow) and disease stage (advanced versus early disease stages) were analyzed. According to this multivariate analysis, the occurrence of the IL-23R gene variant on the donor side reduced the incidence of severe acute GVHD (RR 0.163, 0.041-0.68; (95% CI)) (Po0.011), and acute GVHD grades 2-4 (RR 0.548, 0.311-0.965; (95% CI)) (Po0.037), after transplant.
Discussion
Allogeneic immune responses and autoimmune diseases like Crohn's disease have several clinical features in common and often share the same immunological pathways. 3 Here, we report that an uncommon coding variant of the IL-23R (1142G4A) confers strong protection against the occurrence of severe acute GVHD after transplant as it has been already shown for inflammatory bowel disease recently by Duerr and coworkers and others. 10, 11 The protective effect of the IL-23R gene variant on acute GVHD occurred primarily when the gene variant 
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GVHD % Figure 3 Shows the incidence of acute graft-versus-host disease (GVHD) grades 2-4 in both cohorts together. Only recipients transplanted from donors with the interleukin-23 receptor (IL-23R) gene variant had a reduced incidence of acute GVHD as compared to controls with wild-type IL-23R.
was located on the donor side. This is obvious when considering the fact that the allogeneic immune response is mediated by donor-derived immune competent cells as described in the GVHD cascade early by Ferrara and Antin. 21 Accordingly, we demonstrated previously that variations of NOD2 gene localized on the donor side had protective effects on the occurrence of acute GVHD in patients in contrast to NOD2 gene variants located on the recipient side which were associated with an increased risk for severe acute GVHD. 3 But the detection of the IL-23R 1242G4A gene variant on the recipients side may have some protective influence on the occurrence of severe GVHD as shown here in recipients transplanted from sibling donors of cohort 1. However, these positive results found in the sibling transplant setting have not been confirmed in the unrelated transplant setting of cohort 2 by us. A multivariate analysis confirmed that the glutamine allele of Arg381Gln at the donor side only and not that on the recipient side had a significant influence on the occurrence of severe acute GVHD grades 3-4. This might indicate that the protective effect on the occurrence of GVHD was not strong enough to maintain in the unrelated transplant setting with its numerous divergent influences on the occurrence of GVHD by undetermined antigens such as minor histocombatibility antigens.
IL-12 and IL-23 are expressed by dendritic cells and macrophages in response to stimulation of the innate and adoptive immune system and work together to regulate cellular immune responses. IL-23 is known to induce IFN-g production and proliferation in T cells, preferentially in the CD45R0 memory subsets. 12, 13 In addition to its role in memory T-cell response, IL-23 is a crucial cytokine in the development of a novel CD4 þ T-cell subset characterized by the production of the proinflammatory IL-17, which displays a gene expression and cytokine profile that is distinct from those of Th1 and Th2 cells. Mannon et al. 24 demonstrated in a double-blind clinical trial with 79 patients the successful treatment of active Crohn's disease with a human antibody directed against IL-12. They documented a response rate of 75 against 25% of treatment with placebo after 7 weeks of subcutaneously administration of 3 mg anti-interleukin-12 per kilogram of body weight. Since many immunosuppressive drugs used against Crohn's disease are also effective in the treatment of acute GVHD, it might be possible that anti-interleukin 12 may also help in the treatment of acute GVHD. 25 Although our data support this thesis due to the fact that IL-23 belongs to the IL-12 cytokine family, the presented data suggest more that anti-interleukin 23 might be also effective. Certainly our findings indicate that blockade of the IL-23 signal pathway would be a rational therapeutic strategy for treatment or prophylaxis of acute GVHD. 24 Recently, Krueger et al. 26 performed a double-blind study with a monoclonal antibody against interleukin 12/13 (p40) in 320 patients with psoriasis. They reported no significant increased rate of adverse events of the clinical application of the antibody as compared to placebo. Further, they demonstrated a dose-dependent therapeutic efficacy of the antibody in patients with psoriasis. Therefore, their clinical trial provided further evidence for the role of IL-12 and IL-23 in autoimmune diseases.
We have detected a high frequency of the IL-23R gene variant in both cohorts. In approximately every eighth patient and donor we detected the protective IL-23R gene variant. This high frequency in our study population qualifies the gene variant to be considered in the selection of donors. Patients with a nonprogressive disease who are scheduled for transplant might have an advantage not to suffer from severe acute GVHD when transplanted from a donor with this gene variant. As a result of a lower incidence of acute GVHD rates, we observed also an advantage in the overall survival here for the IL-23R gene variant. So death in remission was lower in patients transplanted from a donor with an IL-23R gene variant, whereas their slightly increased relapse rate was not significantly different. The frequencies of the IL-23R variant allele reported here (5.9-6.9% in the different cohorts) were comparable to that published recently by Duerr et al. 10 in non-Jewish controls (7%).
Our study provides strong evidence that the glutamine allele of Arg381Gln of the IL-23 receptor modify the immune response capacity in patients who underwent allogeneic transplant. In conclusion, such patients may benefit from SNP typing of IL-23R genes. However, more studies about the role of the IL-23R gene variant in the occurrence of GVHD are necessary.
